Alberto Morganti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11936393/publications.pdf

Version: 2024-02-01

		236925	206112
53	2,327	25	48
papers	citations	h-index	g-index
60	60	60	2621
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Genetics, prevalence, screening and confirmation of primary aldosteronism: a position statement and consensus of the Working Group on Endocrine Hypertension of The European Society of Hypertension â´—. Journal of Hypertension, 2020, 38, 1919-1928.	0.5	151
2	The 2020 Italian Society of Arterial Hypertension (SIIA) practical guidelines for the management of primary aldosteronism. International Journal of Cardiology: Hypertension, 2020, 5, 100029.	2.2	69
3	Fibromuscular Dysplasia: From a Rare Cause of Renovascular Hypertension to a More Frequent Systemic Arterial Disease. Updates in Hypertension and Cardiovascular Protection, 2020, , 33-57.	0.1	O
4	First International Consensus on the diagnosis and management of fibromuscular dysplasia. Vascular Medicine, 2019, 24, 164-189.	1.5	232
5	Renin and Prorenin. , 2019, , 478-482.		1
6	First international consensus on the diagnosis and management of fibromuscular dysplasia. Journal of Hypertension, 2019, 37, 229-252.	0.5	80
7	Resistant hypertension: Renal denervation or intensified medical treatment?. European Journal of Internal Medicine, 2018, 50, 6-11.	2.2	12
8	Nocturnal Blood Pressure Dipping is Abolished in Old-Elderly Hospitalized Patients. High Blood Pressure and Cardiovascular Prevention, 2017, 24, 413-417.	2.2	3
9	ABPM Induced Alarm Reaction: A Possible Cause of Overestimation of Daytime Blood Pressure Values Reduced By Treatment with Beta-Blockers. High Blood Pressure and Cardiovascular Prevention, 2016, 23, 255-258.	2.2	2
10	Can an Emotional Reaction Mimicking White-coat Hypertension Cause Hypertensive Crisis and Cardiac Failure?. High Blood Pressure and Cardiovascular Prevention, 2016, 23, 143-145.	2.2	0
11	Clinical validation for the aldosterone-to-renin ratio and aldosterone suppression testing using simultaneous fully automated chemiluminescence immunoassays. Journal of Hypertension, 2015, 33, 2500-2511.	0.5	50
12	European consensus on the diagnosis and management of fibromuscular dysplasia. Journal of Hypertension, 2014, 32, 1367-1378.	0.5	154
13	National Survey on Excellence Centers and Reference Centers for Hypertension Diagnosis and Treatment: Geographical Distribution, Medical Facilities and Diagnostic Opportunities. High Blood Pressure and Cardiovascular Prevention, 2014, 21, 29-36.	2.2	7
14	2012 Consensus Document of the Italian Society of Hypertension (SIIA): Strategies to Improve Blood Pressure Control in Italy. High Blood Pressure and Cardiovascular Prevention, 2013, 20, 45-52.	2.2	57
15	Clinical Management of Renovascular Hypertension. High Blood Pressure and Cardiovascular Prevention, 2013, 20, 257-260.	2.2	4
16	Blood pressure control in Italy. Journal of Hypertension, 2012, 30, 1065-1074.	0.5	78
17	Renal Artery Denervation for Treating Resistant Hypertension. High Blood Pressure and Cardiovascular Prevention, 2012, 19, 237-244.	2.2	19
18	Associations of plasma renin with 10-year cardiovascular mortality, sudden cardiac death, and death due to heart failure. European Heart Journal, 2011, 32, 2642-2649.	2.2	56

#	Article	IF	Citations
19	Aliskiren: the first direct renin inhibitor available for clinical use. Journal of Nephrology, 2011, 24, 541-549.	2.0	25
20	The aldosterone–renin ratio based on the plasma renin activity and the direct renin assay for diagnosing aldosterone-producing adenoma. Journal of Hypertension, 2010, 28, 1892-1899.	0.5	60
21	A comparative study on inter and intralaboratory reproducibility of renin measurement with a conventional enzymatic method and a new chemiluminescent assay of immunoreactive renin. Journal of Hypertension, 2010, 28, 1307-1312.	0.5	42
22	Activity Assays and Immunoassays for Plasma Renin and Prorenin: Information Provided and Precautions Necessary for Accurate Measurement. Clinical Chemistry, 2009, 55, 867-877.	3.2	172
23	Altered Release of Cytochrome P450 Metabolites of Arachidonic Acid in Renovascular Disease. Hypertension, 2008, 51, 1379-1385.	2.7	82
24	Renal artery stenosis and accelerated atherosclerosis: which comes first?. Journal of Hypertension, 2006, 24, 1687-1696.	0.5	22
25	Increased Oxidative Stress and Platelet Activation in Patients With Hypertension and Renovascular Disease. Circulation, 2002, 106, 2800-2805.	1.6	199
26	Supraregional Interlaboratory Quality-Control Survey for an Immunoradiometric Renin Assay. Clinical Chemistry, 2001, 47, 2148-2150.	3.2	7
27	Usefulness and limits of distal echo-doppler velocimetric indices for assessing renal hemodynamics in stenotic and non-stenotic kidneys. Journal of Hypertension, 2001, 19, 1489-1496.	0.5	6
28	Blunted Vascular and Renal Effects of Exogenous Atrial Natriuretic Peptide in Patients with Cushing's Disease. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 1957-1961.	3.6	20
29	Modulation of Sympathetic Coronary Vasoconstriction by Cardiac Renin-Angiotensin System in Human Coronary Heart Disease. Circulation, 2000, 101, 2277-2283.	1.6	26
30	Plasma Endothelin Levels: a Meaningless Number?. Journal of Cardiovascular Pharmacology, 2000, 35, S21-S23.	1.9	15
31	Effects of balloon angioplasty and stent implantation on intrarenal echo-Doppler velocimetric indices. Kidney International, 1998, 53, 1795-1800.	5.2	14
32	Hemodilution Reduces Clinic and Ambulatory Blood Pressure in Polycythemic Patients. Hypertension, 1998, 31, 848-853.	2.7	34
33	Mechanism and Pressor Relevance of the Short-Term Cardiovascular and Renin Excitatory Actions of the Selective A2A-Adenosine Receptor Agonists. Journal of Cardiovascular Pharmacology, 1997, 30, 320-324.	1.9	25
34	Effects of Chronic ACE Inhibition on Sympathetic Nerve Traffic and Baroreflex Control of Circulation in Heart Failure. Circulation, 1997, 96, 1173-1179.	1.6	173
35	Humoral effects of selective adenosine agonists in spontaneously hypertensive rats. Journal of Hypertension, 1996, 14, 75???80.	0.5	6
36	Superiority of acceleration and acceleration time over pulsatility and resistance indices as screening tests for renal artery stenosis. Journal of Hypertension, 1996, 14, 1229-1235.	0.5	34

#	Article	IF	CITATIONS
37	Effects of exposure to high altitude on plasma endothelin-1 levels in normal subjects. Journal of Hypertension, 1995, 13, 859-865.	0.5	38
38	Hemodynamic and Humoral Effects of Chronic Treatment with the Neutral Endopeptidase Inhibitor SCH 42495 in Spontaneously Hypertensive Rats. Journal of Cardiovascular Pharmacology, 1994, 23, 703-708.	1.9	9
39	Abnormal hemodynamics and elevated angiotensin II plasma levels in polydipsic patients on regular hemodialysis treatment. Kidney International, 1993, 44, 107-114.	5.2	40
40	Regulation of vasopressin release in moderately severe essential hypertension. Clinical Autonomic Research, 1991, 1, 109-114.	2.5	6
41	Investigation of reflexes from volume and baroreceptors during converting-enzyme inhibition in humans. American Heart Journal, 1989, 117, 740-745.	2.7	19
42	Effect of angiotensin converting enzyme inhibition on cardiovascular regulation during reflex sympathetic activation in sodium-replete patients with essential hypertension. Journal of Hypertension, 1989, 7, 825-835.	0.5	30
43	The effects of Mianserin therapy on plasma renin activity in depressed patients. Biological Psychiatry, 1986, 21, 1331-1334.	1.3	3
44	Participation of the Renin-angiotensin System in the Maintenance of Blood Pressure During Changes in Posture in Patients with Essential Hypertension. Journal of Hypertension, 1985, 3, 55-61.	0.5	13
45	Plasma Catecholamines and Cardiovascular Responses During Converting Enzyme Inhibition in Normotensive and Hypertensive man. Clinical and Experimental Hypertension, 1982, 4, 761-789.	0.3	16
46	Renin Responsiveness to Neural and Nonneural-Mediated Stimuli in the Renin Subgroups of Essential Hypertension., 1981,, 236-239.		0
47	Endocrine and Cardiovascular Influences of Converting Enzyme Inhibition with SQ 14225 in Hypertensive Patients in the Supine Position and during Head-Up Tilt before and after Sodium Depletion*. Journal of Clinical Endocrinology and Metabolism, 1980, 50, 748-754.	3.6	36
48	High and low renin subgroups of essential hypertension: Differences and similarities in their renin and sympathetic responses to neural and nonneural stimuli. American Journal of Cardiology, 1980, 46, 306-312.	1.6	6
49	Contrasting effects of acute beta blockade with propranolol on plasma catecholamines and renin in essential hypertension: a possible basis for the delayed antihypertensive response. American Heart Journal, 1979, 98, 490-494.	2.7	34
50	Role of the sympathetic nervous system in mediating the renin response to head-up tilt. American Journal of Cardiology, 1979, 43, 600-604.	1.6	45
51	BETA-BLOCKADE AND BLOOD-LEVELS AFTER LOW-DOSE ORAL PROPRANOLOL: THE HEPATIC "FIRST-PASS" THRESHOLD REVISITED. Lancet, The, 1978, 311, 407-410.	13.7	13
52	Relation between the hypotensive and renin-suppressing activities of alpha methyldopa in hypertensive patients. American Journal of Cardiology, 1977, 40, 762-767.	1.6	6
53	Control of renin release: A review of experimental evidence and clinical implications. American Journal of Cardiology, 1976, 37, 675-691.	1.6	76